Metastatic medullary thyroid carcinoma masquerading as breast lesion: lessons from a rare case
DOI:
https://doi.org/10.18203/2349-2902.isj20253862Keywords:
Medullary thyroid carcinoma, Breast metastasis, Calcitonin, Rare metastasis, Case reportAbstract
Medullary thyroid carcinoma (MTC), derived from parafollicular C-cells, accounts for 5–8% of thyroid malignancies. It has a propensity for hematogenous metastasis, commonly involving liver, lungs, and bones. Breast metastases from MTC are exceedingly rare, with about 40 documented cases reported worldwide. Herein this case describes a 25-year-old female who initially underwent total thyroidectomy and right cervical lymphadenectomy for MTC, staged as pT3bN1bM0 (stage IVA). Following surgery and adjuvant radiotherapy, she developed persistently elevated calcitonin levels. Subsequent Ga-68 DOTANOC PET-CT revealed local recurrence, but the patient declined re-exploration. Three years later, she presented with a breast lump, clinically and radiologically suspected to be fibroadenoma. Wide local excision with intraoperative frozen section revealed metastatic MTC. Immunohistochemistry confirmed the diagnosis (INSM1 positive, GATA3 negative). Breast metastasis from MTC is extremely uncommon and may mimic benign breast lesions, delaying diagnosis. This case highlights the importance of calcitonin surveillance, the role of intraoperative frozen section, and immunohistochemistry in differentiating metastatic MTC from primary breast tumors.
Metrics
References
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. DOI: https://doi.org/10.1089/thy.2014.0335
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139-48. DOI: https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299-310. DOI: https://doi.org/10.1111/j.1365-2265.2004.02037.x
Fatma S, Maha C, Ines Z, Salma K, Yoldez H, Souhail J, et al. Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report. BMC Womens Health. 2025;25(1):29. DOI: https://doi.org/10.1186/s12905-025-03564-y
Meng K, Chen W, Tian W, Sun K, Chen H. Medullary thyroid carcinoma with breast metastasis: Two case reports. Medicine (Baltimore). 2018;97(47):e13193. DOI: https://doi.org/10.1097/MD.0000000000013193
Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid carcinoma patients: proposal for a revised staging system. Ann Surg. 2013;257(2):323-9. DOI: https://doi.org/10.1097/SLA.0b013e318268301d
Taccaliti A, Silvetti F, Palmonella G, Boscaro M. Medullary thyroid carcinoma: a review. Biomed Pharmacother. 2004;58(9):517-21.
Lips CJ, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem. 2001;38:168-79. DOI: https://doi.org/10.1258/0004563011900614
Rooper LM, Sharma R, Bishop JA. INSM1 demonstrates superior performance to the individual and combined use of conventional neuroendocrine markers in head and neck neuroendocrine carcinomas. Am J Surg Pathol. 2020;44(3):368-76.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639-46. DOI: https://doi.org/10.1200/JCO.2012.48.4659